BAP1 and mesothelioma: In fact, while some studies have shown combinatorial treatment with cisplatin and olaparib is effective in mesothelioma cells with a defective HR (137), another study has demonstrated that olaparib has limited anti-tumor activity also in BAP1 mutated patients (NCT03531840).